This study was conducted to investigate the effects of α-lipoic acid and coenzyme Q10 on plasma levels of lipids, asymmetric dimethylarginine, oxidative stress in fructose fed rats which provide a model of dietary-induced insulin resistance and to evaluate vascular changes developing in these rats by histologically. Male Sprague Dawley rats were used in this study. The animals were divided into 4 groups. Group 1 did not receive any medication and served as a control. Group 2 received a regular diet and water ad libitum and fructose was administered as 10% solution in drinking water. Group 3 received α-lipoic acid (100 mg/kg/day) i.p. for 5 weeks and Group 4 received coenzyme Q10 (10 mg/kg/day) i.p. for 5 weeks. For determination of plasma asymmetric dimethylarginine, glutathione and malondialdehyde levels, high-performance liquid chromatography system was used. Homeostatic model assessment was used to measure insulin resistance was calculated. Lipid profile measurements were determined using enzymatic assay on an Auto analyzer. The high fructose diet was significantly associated with an increase in levels of plasma LDL, VLDL and total cholesterol and decrease in level of HDL cholesterol. Plasma asymmetric dimethylarginine, malondialdehyde and glutathione levels were also increase in these rats. α-lipoic acid or coenzyme Q10 supplementation was found to have some positive effect on these parameters. These findings were also demonstrated by morphological observation of the aorta. We demonstrated that administration of α-lipoic acid and coenzyme Q10 notably suppresses oxidative and nitrative stress, hyperinsulinemia, insulin resistance developing in fructose fed rats, a model of metabolic syndrome (MS). These positive effects of α-lipoic acid or coenzyme Q10 can be attributed to its antioxidant activity.

Key Words: metabolic syndrome, coenzyme Q10, α-lipoic acid, ADMA, oxidative stress

Metabolic syndrome (MS) characterized by hyperglycemia, hyperlipidemia and hypertension is a significant risk factor for cardiovascular disease.(1) Insulin resistance (IR) is a central component of metabolic syndrome.(2) Fructose-fed rats (FFRs) provide a model of dietary-induced insulin resistance to indicate the pathophysiological mechanisms (metabolic and cardiovascular changes) associated with MS.(3,4) The metabolic effect of a fructose diet is associated with oxidative stress,(5) but the precise mechanism is not fully understood. Reactive oxygen species (ROS) play a physiological role in the vessel wall. Dietary factors play a key role in the development or prevention of various human diseases, including cardiovascular disease and MS.(6) Some studies suggest a strong association between IR and endothelial dysfunction.(7) Endothelium-derived nitric oxide (NO) is the most potent endogenous substance which is synthesized by the endothelial enzyme NO synthase (e-NOS) from the amino acid L-arginine.(8) Experimental and clinical data show that endogenous inhibitors of e-NOS, such as asymmetric dimethylarginine (ADMA), may be responsible for endothelial dysfunction in which ADMA plasma levels have been found elevated.(9–14) Therefore, ADMA plasma levels appear to be dynamically regulated and can be correlated with measure of NO bioavailability. Endothelial dysfunction induces a reduction in vascular relaxation, linked to a decrease in the bioavailability of nitric oxide (NO)(15) and an increase in levels of oxidative stress(16) following the overproduction of super oxide anion (O2−). The role of oxidative stress in the development of IR has been demonstrated by several studies.(17) Furthermore, systemic oxidative stress is associated with insulin resistance.(18–20)

Coenzyme Q10 (CoQ10) is an electron carrier in the mitochondrial respiratory chain. In addition to its role in mitochondria, CoQ10 acts as an antioxidant, scavenging free radicals and inhibiting lipid peroxidation.(21,22) Recent studies have provided beneficial effects of CoQ10 in various disorders related to oxidative stress like hypertension and heart failure.(23–25) It has been reported that CoQ10 concentrations and redox status are associated with components of MS.(26) α-lipoic acid (ALA), also known as 6,8-thioctic acid has generated considerable clinical interest as a redox-modulating agent.(27) Biologically, α-lipoic acid functions as a cofactor of oxidative decarboxylation reactions in glucose metabolism to provide energy.(28) It has been used in the western world for a long time to treat complications associated with diabetes.(29) In addition to its role in glucose metabolism, but may also acts as an antioxidant in vitro and in vivo.(30) In vitro experiments have shown that ALA is potent scavengers of reactive oxygen species which quenches singlet oxygen, hydroxyl radical and hypochlorous acid.(31)

Thus, it would be important to establish whether exogenous administration of CoQ10 and ALA are effective for prophylaxis and therapy of MS. This study aimed to investigate the effect of exogenous CoQ10 and ALA administration in the fructose-fed rat on the levels of lipids, ADMA, NO and glutathione. We also investigated the possible protective effects of coenzyme Q10 and ALA on the vascular changes developed in these rats by histologically.

Materials and Methods

Animals and treatment. Male Sprague Dawley rats of body weight ranging from 210 to 230 g were used in this study. They were housed in an animal room under controlled conditions on a 12-h light/dark cycle and constant temperature (22°C). Food and water were supplied ad libitum. All rats were fed a standard rat chow before beginning the study and continued to consume standard rat chow composed of 21% protein, 4% fat, 50% carbohydrate (vegetable starch), and 4.5% cellulose for the entire study duration. Both diets contained a standard mineral and vitamin mixture. All protocols described were reviewed and approved by the Local Institutional Committee for the Ethical Use of Animals.
The animals were divided into 4 groups and were maintained as follows:

Group 1 (CON) (n = 7) – This group received regular diet and water ad libitum. This group did not receive any medication and served as a control. After 8 weeks, this group received serum physiologic (SF) (0.5 mL/day) intraperitoneally (i.p.) for 5 weeks.

Group 2 (FRU) (n = 9) – This group received a regular diet and water ad libitum and fructose was administered as % 10 solution in drinking water. After 8 weeks, this group received SF (0.5 mL/day) i.p. for 5 weeks.

The other groups of rats were given one of the following treatments (Group 3 and 4).

Group 3 (FRU + ALA) (n = 9) – This group received a regular diet and water ad libitum and fructose was administered as % 10 solution in drinking water. After 8 weeks, this group received ALA (100 mg/kg/day) i.p. for 5 weeks.

Group 4 (FRU + CoQ10) (n = 9) – This group received a regular diet and water ad libitum and fructose was administered as % 10 solution in drinking water. After 8 weeks, this group received CoQ10 (10 mg/kg/day) i.p. for 5 weeks.

Body weights of animals were recorded at the baseline and after the treatment. Blood samples from animals were collected by decapitation and serum was separated by centrifugation and samples were kept at −70°C until the measurements were performed.

**Biochemical analysis.** Serum samples were analyzed for glucose, triglyceride (TG), HDL-cholesterol, LDL-cholesterol and total cholesterol (TC). Glucose and lipid profile measurement were determined using enzymatic assay on an Auto analyzer (Olympus AU 600, Hamburg, Germany). Quantitative determination of serum insulin concentration was performed with rat/mouse Enzyme-linked immunosorben essay (ELISA) kit (Linco research). Insulin levels were expressed as ng/mL in ELISA kit and they were converted to mU/ml. Homeostatic model assessment (HOMA) as a measure of insulin resistance was calculated by the formula: insulin (mU/ml) × [glucose (mmol/l/22.5)].

For determination of plasma ADMA levels, HPLC system was used. This method allows to analyzed the asymmetric dimethylarginine (ADMA) with clean-up columns procedure and derivatization. Besides this method allows to analyze the arginine and symmetric dimethylarginine (SDMA). After derivatization, 50 μl of solution are injected in HPLC system and analyzed by Fluorescence. The sensitivity of this method was <0.01 μmol/l and linearity was >16.00 μmol/l.

Determinations of total and reduced glutathione (GSH) were determined by HPLC. EDTA-blood was used in this test system. For the determination of glutathione the sample is divided in two aliquots. One is reduced and the total amount of glutathione is measured. The other aliquot is treated without reduction solution, which determines only the reduced glutathione. During the derivatisation reaction glutathione is converted into a fluorescent probe. The following precipitation step removes high molecular substances. After centrifugation the fluorescent probe is cooled (2–8°C) and injected into the HPLC system. The isocratic separation via HPLC at 30°C using a reversed phase column in two runs. One run lasts 4 min. The chromatograms are recorded by a fluorescence detector. The quantification is performed with the delivered EDTA-blood calibrator; the concentration is calculated by the internal standard method. The amount of oxidized glutathione is calculated by subtraction of: GSHtotal−GSHreduced the difference was divided by two because oxidized glutathione (GSSG) consists of two reduced GSH molecules. Intra-Assay CV for GSHtotal is 1.2% (551 μmol/l) and for GSHreduced is 1.2% (286 μmol/l). Inter-Assay CV for GSHtotal is 2.8% (554 μmol/l) and for GSHreduced is 3.5% (271 μmol/l).

Determination of plasma MDA level was also determined by HPLC. For the determination of malondialdehyde a derivatisation step, in which protein bound malondialdehyde is hydrolysed and converted into a fluorescent probe (60 min at 95°C) is performed. The fluorescent probe is then cooled (2–8°C), centrifuged, mixed with a reaction solution and injected into the HPLC system. The isocratic separation via HPLC at 30°C, using a ‘reversed phase’ column, lasts 4 min for one sample. The chromatograms are recorded by a fluorescence detector. The quantification is performed with the delivered calibrator; the concentration is calculated via integration of the peak heights. Intra-Assay CV: 6.4% (2.55 μmol/l) Inter-Assay CV: 7.5% (2.50 μmol/l) [n = 6].

Plasma NO levels were measured in triplicate after conversion of nitrate to nitrite by nitrate reductase, and nitrite was measured by using the Griess reaction, as described previously.(32) The results were expressed as μmol/ml.

**Vascular histological analysis.** Fixations of vessel samples obtained from control and other groups were made in % 10 formaldehyde. After that, paraffin sections at 4 micron thickness obtained from routine pathological processes were stained with hematoxylin-eosin and examined by light microscopy.

**Statistical analysis.** The results are expressed as mean ± SD. Analysis of the data was performed by one-way analysis of variance (ANOVA) and subsequent analysis was performed using the Tukey test. The p values smaller than 0.05 were selected to indicate statistical significance between groups.

**Results**

**Body weight, glucose, HOMA-IR and lipid profile.** Fructose fed rats had a significant increase in body weight. Fructose fed rats had a higher body weight compared with controls (p<0.0001). ALA and CoQ10 treatment given to fructose fed rats for 8 weeks affect body weight gain during the experimental period. Body weights were decreased during the treatment of ALA and CoQ10 at the end of the experiment compared with only fructose fed rats (p<0.05, p<0.01). Serum levels of LDL, TG and total cholesterol were increased and HDL cholesterol was decreased in fructose fed rats compared with control rats at the end of the experiment (p<0.0001). The treatment of ALA and coenzyme Q10 at the end of experiment improved the lipid levels. Serum levels of LDL, TG and total cholesterol were significantly decreased and HDL cholesterol was significantly increased in group 3 and 4 compared with fructose fed rats (p<0.0001). But there were no significant difference between ALA treatment and Coenzyme Q10 treatment (Table 1).

In the end of the experiments, the highest levels of glucose and HOMA-IR were observed in the fructose fed group compared with control, group 3 and group 4 (p<0.0001, p<0.05, p<0.01 respectively). Administration of ALA and CoQ10 were improved the glucose and HOMA-IR levels. Treatment with ALA and CoQ10 were significantly decreased the glucose level compared with fructose fed rats (p<0.0001), but as shown in lipid levels, there were no significant difference in glucose levels between ALA and CoQ10 treatment. HOMA-IR level was decreased in ALA treatment group compared with fructose fed group (p<0.001). Coenzyme Q10 administration more improved HOMA-IR than ALA treatment. HOMA-IR was significantly decreased in this group compared with fructose fed rats (p<0.0001).

**Levels of ADMA, MDA, NO, total glutathione, reduced glutathione and NO.** The high fructose diet was significantly associated with an increase in levels of plasma ADMA (0.95 ± 0.21 μmol/L vs 2.51 ± 1.19 μmol/L, p<0.0001) leading to a significant reduction in the L-arginine level (81.39 ± 6.92 μmol/l vs 71.08 ± 8.35 μmol/l, p<0.05). No significant difference was seen in the levels of SDMA between control and fructose fed rats. ALA and CoQ10 administration were decreased ADMA levels compared with controls (p<0.01, p<0.001, respectively). MDA and NO levels were lead similar effects as shown in ADMA levels. These parameters were increased in high fructose diet group compared with controls (p<0.0001) and treatment with ALA or CoQ10 decreased the levels of MDA and NO levels.
In this study, we found that ALA or Coenzyme Q10 administration prevent the increase of ADMA, the development of insulin resistance, oxidative stress, and vascular changes in an experimental model of metabolic syndrome induced by fructose administration. Insulin resistance has been implicated as a central pathogenic feature of MS in human and animal models. As shown in previous studies reported by a group, treatments of ALA and CoQ10 not only prevented the increase in ADMA and oxidative stress but also reduced vascular perivascular lymphocytic infiltration and edema in FFRs. The fructose rich diet used in our experimental model induced the development of pathophysiological characteristics associated with metabolic syndrome, including hyperglycemia and dyslipidemia. Our results are in accordance with a recent study which indicated that fructose-fed Sprague–Dawley rats manifested major characteristics of human metabolic syndrome. Fructose is a simple carbohydrate, with interesting physico-chemical properties such as its strong sweetening power and its hygroscopic nature. The highest concentration of fructose found in natural foods is about 42%, and it is the principal sugar added to processed foods. About 75% of the total fructose intake in the United States is derived from soft drinks. Fructose is the major characteristic of human metabolic syndrome. Fructose is a simple carbohydrate, with interesting physico-chemical properties such as its strong sweetening power and its hygroscopic nature.

To further investigate the relationships between biochemical characteristics and HOMA-IR as continuous variables, the following statistical correlations were identified: ADMA (r = 0.55, p = 0.001), glutathione_{total} (r = 0.43, p = 0.001), glutathione_{reduced} (r = 0.43, p = 0.001), MDA (r = 0.49, p = 0.001) and NO (r = 0.44, p = 0.001) (Table 3).

**Morphological observation of the aorta.** When compared with control group (Fig. 1), histopathological examination of vessels of group 2 revealed that they were lymphocytic infiltration in place, hypertrophy of smooth muscles and edema (Fig. 2–4); in ALA-administered group, it was noted that perivascular lymphocytic infiltration was significantly decreased and even disappeared completely in place (Fig. 5). In CoQ10-administered group, appearances of vessels were almost same with control group and poor lymphocytic infiltration was seen in perivascular area (Fig. 6).

**Discussion**

In this study, we found that ALA or Coenzyme Q10 administration prevent the increase of ADMA, the development of insulin resistance, oxidative stress, and vascular changes in an experimental model of metabolic syndrome induced by fructose administration. Insulin resistance has been implicated as a central pathogenic feature of MS in human and animal models. As shown in previous studies reported by a group, treatments of ALA and CoQ10 not only prevented the increase in ADMA and oxidative stress but also reduced vascular perivascular lymphocytic infiltration and edema in FFRs. The fructose rich diet used in our experimental model induced the development of pathophysiological characteristics associated with metabolic syndrome, including hyperglycemia and dyslipidemia. Our results are in accordance with a recent study which indicated that fructose-fed Sprague–Dawley rats manifested major characteristics of human metabolic syndrome. Fructose is a simple carbohydrate, with interesting physico-chemical properties such as its strong sweetening power and its hygroscopic nature. The highest concentration of fructose found in natural foods is about 42%, and it is the principal sugar added to processed foods. Unlike glucose, fructose does not directly stimulate insulin secretion because pancreatic beta-cells have very low levels of the fructose transporter GLUT5. An additional important observation in this study pertained to the weight loss noted with ALA. α-lipoic acid has been described to have appetite suppressant effect through an AMP kinase mechanism in the

**Table 1. Changes in body weight and serum lipids**

|                          | Group 1 (CONTROL) | Group 2 (FRU) | Group 3 (FRU + ALA) | Group 4 (FRU + CoQ10) |
|--------------------------|-------------------|---------------|---------------------|-----------------------|
| n                        | 7                 | 9             | 9                   | 9                     |
| Body weight (g) (Initial) | 212.57 ± 11.04    | 218.66 ± 9.65 | 219.44 ± 15.28      | 220.55 ± 13.21        |
| Body weight (g) (Final)  | 312.71 ± 6.15     | 362.11 ± 20.03** | 345.22 ± 13.31*     | 342.11 ± 12.46*       |
| Glucose (mg/dl)          | 98.57 ± 6.42      | 147.88 ± 8.97* | 115.44 ± 6.98**     | 109.66 ± 4.58**       |
| LDL-C (mg/dl)            | 28.28 ± 3.19      | 59.88 ± 3.68*  | 38.55 ± 6.10**      | 34.22 ± 4.43**        |
| VLDL-C (mg/dl)           | 20.48 ± 1.37      | 33.97 ± 1.68*  | 25.26 ± 1.54**      | 24.82 ± 1.36**        |
| Triglycerides (mg/dl)    | 102.42 ± 6.87     | 169.88 ± 8.44* | 126.33 ± 7.71**     | 124.11 ± 6.80**       |
| Total-C (mg/dl)          | 82.57 ± 4.15      | 118.22 ± 3.89* | 97.22 ± 8.52**      | 96.00 ± 6.63**        |
| HDL-C (mg/dl)            | 34.14 ± 2.79      | 25.11 ± 4.13*  | 35.77 ± 5.09*       | 37.11 ± 4.07*         |

*p<0.0001, compared with control; *p<0.05, compared with group 3; *p<0.01, compared with group 4; *p<0.005, compared with control; *p<0.0001, compared with group 2; *p<0.05, compared with control.

**Table 2. Effects of ALA and CoQ10 treatments on plasma variables in rats**

|                          | Group 1 (CONTROL) | Group 2 (FRU) | Group 3 (FRU + ALA) | Group 4 (FRU + CoQ10) |
|--------------------------|-------------------|---------------|---------------------|-----------------------|
| n                        | 7                 | 9             | 9                   | 9                     |
| ADMA (μmol/l)            | 0.95 ± 0.21       | 2.51 ± 1.19*  | 1.61 ± 0.27*        | 1.39 ± 0.30*          |
| SADMA (μmol/l)           | 0.66 ± 0.14       | 0.87 ± 0.42   | 0.46 ± 0.09*        | 0.75 ± 0.24           |
| ARJININ (μmol/l)         | 81.39 ± 6.92      | 71.08 ± 8.35* | 74.54 ± 6.08        | 82.54 ± 11.56o        |
| Insulin (ng/ml)          | 0.41 ± 0.14       | 0.93 ± 0.14*  | 0.68 ± 0.11*        | 0.67 ± 0.12α          |
| HOMA                      | 2.44 ± 0.98       | 8.19 ± 1.69*  | 4.67 ± 1.01i        | 4.41 ± 1.00h          |
| Reduced glutathione (μmol/l) | 829.42 ± 35.00 | 682.44 ± 76.61* | 732.11 ± 38.72j     | 757.88 ± 16.03kk     |
| Total glutathione (μmol/l) | 848.57 ± 34.23 | 736.11 ± 74.70* | 753.66 ± 42.06*     | 778.66 ± 17.08h      |
| MDA (μmol/l)             | 1.98 ± 0.47       | 3.21 ± 0.47*  | 2.66 ± 0.88i        | 2.52 ± 0.21i          |
| NO (μmol/ml)             | 56.82 ± 10.39     | 84.67 ± 15.93* | 71.01 ± 14.12i      | 71.71 ± 6.64kk       |

*p<0.0001, compared with control; *p<0.01, compared with group 2; *p<0.001, compared with group 4; *p<0.005, compared with group 4; *p<0.05, compared with control; *p<0.001, compared with group 2; *p<0.05, compared with control.

**Table 3. Correlation HOMA and some of biochemical parameters**

|                  | r     | p     |
|------------------|-------|-------|
| ADMA             | 0.55  | 0.001 |
| Reduced glutathione | -0.6  | 0.0001|
| Total glutathione  | -0.46 | 0.006 |
| NO               | 0.44  | 0.009 |
The present study had shown that fructose rich diet in rats leads to dyslipidemia condition. The increase in TC, LDL-C, and triglycerides as well as decrease in HDL-C concentrations may be as a result of reduced lipoprotein lipase activity secondary to reduced in plasma insulin levels. Cholesterol ester transfer protein, which is important in regulating lipoprotein lipid composition, was increased in DM condition, which may have contributed to the dyslipidemia. ALA and coenzyme Q10 supplementation corrected the dyslipidemia occurred. The mechanism action of ALA is believed through the controlling the activity of enzyme that involved in lipid metabolism. ALA was found to increase 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity and increase lipoprotein lipase and lecithin cholesterol acyl transferase (LCAT).

Glucose autoxidation and glycation of protein leads to generation of oxygen free radicals, which can enhance lipid peroxidation and oxidation of LDL. Fructose fed rats showed significant...
increase in serum total cholesterol, triglycerides, VLDL, LDL and decrease in HDL levels. Treatment with CoQ10 significantly decreased serum cholesterol, triglycerides, VLDL, LDL and increased HDL levels in diabetic treated rats. Singh et al. reported that HDL-C concentrations significantly increased in the group treated by 120 mg/day of CoQ10 than in the control group. The reduction in lipid levels and increase in HDL levels may be due to inhibition of LDL oxidation and reduce oxidative stress.

We found that a long-term fructose-rich diet was associated with an increase in oxidative stress. The increased production of MDA, nitric oxide, total glutathione and reduced glutathione in plasma was detected. In the present experiments, CoQ10 and ALA were used to test the effects of antioxidants on high-fructose diets CoQ10 and ALA were associated with statistically significant positive effects. Previous work carried out on ‘ALA supplementation using the same dose in diabetic rats’ demonstrated beneficial effects via changes in the oxidative state. Previous reports confirmed that ALA scavenges hydroxyl radicals, hydrogen peroxide (H$_2$O$_2$), singlet oxygen, superoxide radicals, and peroxyl radicals thereby preventing the free radicals-mediated lipid peroxidation. GSH is the intracellular non-protein sulphydryl compound that act as both nucleophile and an effective reductant by interacting with various electrophile and oxidized compounds, and its depletion results in increased defenselessness of cell to oxidative stress. The consequence of decrease in cellular GSH levels is an increase of free radical intermediates leading to oxidative stress and potent cellular damage. The reduced form of GSH becomes readily oxidized to oxidized glutathione (GSSG) with the Glutathion peroksidaz (GSH-Px) on interacting with free radicals. In our present study, pretreatment of the rats with ALA significantly increased the concentration of GSH. It has been known that the ALA plays an important role in improving the GSH status through the mechanism of increasing the cystine availability because cystine is the rate-limiting factor in GSH biosynthesis. ALA induces the cystine uptake and thereby increases GSH synthesis. In our present investigation, pretreatment with ALA augmented the serum GSH level which is in accordance with the previous studies.

Impaired endothelium-dependent relaxation has been demonstrated in various vascular beds in different animal models of diabetes. The potent antioxidant capacity of ALA, which reduces oxidative stress both at systemic and local levels, was responsible for its beneficial action on atherosclerosis and vascular relaxation. In a recent study, ALA was directly linked to ability to reduce significantly the elevated total nitrate/nitrite levels of combination therapy using the same dose in diabetic rats’ demonstrated beneficial effects. Previous work carried out on ‘ALA supplementations in high glucose conditions’ showed that the ALA administration reduced oxidative stress. The increased production of MDA, nitric oxide, total glutathione and reduced glutathione in plasma was detected. In the present experiments, CoQ10 and ALA were used to test the effects of antioxidants on high-fructose diets CoQ10 and ALA were associated with statistically significant positive effects. Previous work carried out on ‘ALA supplementation using the same dose in diabetic rats’ demonstrated beneficial effects via changes in the oxidative state.

References

1. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999; 84: 111–141.
2. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88: 2399–2403.
3. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512–516.
4. Miattello R, Cruzado M, Risler N. Mechanisms of cardiovascular changes in an experimental model of syndrome X and pharmacological intervention on the renin-angiotensin-system. Curr Vasc Pharmacol 2004; 2: 371–377.
5. Nyby MD, Abedi K, Smutko V, Eslami P, Tuck ML. Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res 2007; 30: 451–457.
6. Scheen A. Management of the metabolic syndrome. Minerva Endocrinol 2004; 29: 31–45.
7 Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601–2610.

8 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–376.

9 Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575.

10 Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-sadenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 105.

11 Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039–2044.

12 Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 933–938.

13 Kielstein JT, Böger RH, Bode-Böger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170–176.

14 Zoccali C, Bode-Böger S, Mallamaci F, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 933–938.

15 Sato Y, Ito T, Udaka N, et al. Immunohistochemical localization of facilitated-diffusion glucose transporters in rat pancreatic islets. Tissue Cell 1996; 28: 637–643.

16 Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004; 10: 727–733.

17 Wasan KM, Ng SP, Wong W, Rodrigues BB. Streptozotocin- and alloxan-induced diabetes modifies total plasma and lipoprotein lipid concentration and composition without altering cholesteryl ester transfer activity. Pharmacol Toxicol 1998; 83: 169–175.

18 Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Effect of alpha-lipoic acids on lipid profile in rats fed a high-fructose diet. Exp Diabesity Res 2004; 5: 195–200.

19 Wolff SP, Dean RT. Glucos autoxidation and protein modification. The potential role ‘autoxidative glycosylation’ in diabetes. Biochem J 1987; 245: 243–250.

20 Singh RB, Neki NS, Kartiky K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75–82.

21 Stevens MJ, Obrosova I, Cao X, Van Huyzen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006–1015.

22 Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic as biological antioxidant. Comparison of the two commonly used animal models. Am J Hypertens 2008; 21: 1018–1022.

23 Sato Y, Ito T, Udaka N, et al. Immunohistochemical localization of facilitated-diffusion glucose transporters in rat pancreatic islets. Tissue Cell 1996; 28: 637–643.

24 Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004; 10: 727–733.

25 Wasan KM, Ng SP, Wong W, Rodrigues BB. Streptozotocin- and alloxan-induced diabetes modifies total plasma and lipoprotein lipid concentration and composition without altering cholesteryl ester transfer activity. Pharmacol Toxicol 1998; 83: 169–175.

26 Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Effect of alpha-lipoic acids on lipid profile in rats fed a high-fructose diet. Exp Diabesity Res 2004; 5: 195–200.

27 Wolff SP, Dean RT. Glucos autoxidation and protein modification. The potential role ‘autoxidative glycosylation’ in diabetes. Biochem J 1987; 245: 243–250.

28 Singh RB, Neki NS, Kartiky K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75–82.

29 Atmaca G. Antioxidant effect of sulfur-containing amino acid. Tonus Med J 2004; 45: 776–788.

30 Bose KS, Agrawal BK. Effect of lycopene from cooked tomatoes on serum antioxidant enzymes, lipid peroxidation rate and lipid profile in coronary heart disease. Singapore Med J 2007; 48: 415–420.

31 Butzer U, Weidenbach H, Gansauge S, Gansauge F, Beger HG, Nussler AK. Increased oxidative stress in the RAW 264.7 macrophage cell line is partially mediated via the S-nitrosothiol-induced inhibition of glutathione reductase. FEBS Lett 1999; 445: 274–278.

32 Han D, Handleman G, Marcocci L, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 933–938.

33 Kielstein JT, Böger RH, Bode-Böger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170–176.

34 Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117.

35 Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817–826.

36 Heitzer T, Schlinzig T, Krohn K, Meintz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–2678.

37 Delbosc S, Paizanis E, Magous R, et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005; 179: 43–49.

38 Fujita K, Nishikawa H, Furunashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437–1442.

39 Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002; 252: 440–447.

40 Lapointe A, Couillard C, Piche ME, et al. Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis 2007; 191: 362–368.

41 Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA 1990; 87: 4879–4883.

42 Ersnt L, Dalnegn G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195–204.

43 Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007; 21: 297–306.

44 Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion 2007; 7 Suppl: S154–S167.

45 Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev 2007; 65: 286–293.

46 Miles MV, Morrison JA, Horn PS, Tang PH, Pesce AJ. Coenzyme Q10 changes are associated with metabolic syndrome. Clin Chim Acta 2004; 344: 173–179.

47 Arvazlakhan P, Panneerselvam C. Effect of DL-alpha-lipoic acid on neural antioxidants in aged rats. Pharmacol Res 2000; 42: 219–222.

48 Pari L, Latha M. Antidiabetic effect of Scoparia dulcis: effect on lipid peroxidation in streptozotocin diabetes. Gen Physiol Biophys 2005; 24: 13–26.

49 Henriksen EJ. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 2006; 40: 3–12.

50 Maragoni K, Devaraj S, Tirosch O, Packer L, Jialal I. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med 1999; 27: 1114–1121.
hepatic and renal damage. *Toxicology* 2008; **243**: 261–270.

54 Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant alipoic acid. *Gen Pharmacol* 1997; **29**: 315–331.

55 Nakagawa H, Sumiki E, Takusagawa M, Ikota N, Matsushima Y, Ozawa T. Scavengers for peroxynitrite: inhibition of tyrosine nitration and oxidation with tryptamine derivatives, alpha-lipoic acid synthetic compound. *Chem Pharm Bull* 2000; **48**: 261–265.

56 Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. *Curr Opin Clin Nutr Metab Care* 2005; **8**: 641–646.

57 Quiles JL, Ochoa JJ, Battino M, *et al.* Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage. *Biofactors* 2005; **25**: 73–86.

58 Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002; **56**: 1137–1142.

59 Singh RB, Niaz MA. Serum concentration of lipoprotein (a) decreases on treatment with hydroxysoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. *Int J Cardiol* 1999; **68**: 23–29.

60 Miyazaki H, Matsuoka H, Cooke JP, *et al.* Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. *Circulation* 1999; **99**: 1141–1146.

61 Lin KY, Ito A, Asagami T, *et al.* Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation* 2002; **106**: 987–992.

62 Leiper JM, Santa Maria J, Chubb A, *et al.* Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. *Biochem J* 1999; **343**: 209–214.

63 Matsuoka H, Itoh S, Kimoto M, *et al.* Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. *Hypertension* 1997; **29**: 242–247.

64 Päivä H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. *J Am Coll Cardiol* 2002; **40**: 1241–1247.

65 Takuchi S, Fujii H, Kamide K, *et al.* Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. *Am J Hypertens* 2004; **17**: 802–808.

66 Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. *Circulation* 1999; **99**: 3092–3095.

67 MacAllister RJ, Parry H, Kimoto M, *et al.* Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. *Br J Pharmacol* 1996; **119**: 1533–1540.

68 Chang JW, Lee EK, Kim TH, *et al.* Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. *Am J Nephrol* 2007; **27**: 70–74.